Morvus Technology Limited is a privately owned pharmaceutical company specialising in the discovery and development of novel drugs and diagnostics for the oncology sector. It has offices near Brecon, Wales. Morvus was formed in 2004 after the founders’ previous company, Enact Pharma plc, was acquired. Initially based on the Porton Down Science Park, near Salisbury, in 2007 the company relocated, with considerable assistance from the Welsh Government, to its present site. The company has a diverse portfolio of oncology therapeutics and diagnostics and its lead drug is a potent anti-tumour agent that displays minimal toxicity to normal tissues and is rendered harmless in the circulation. Morvus is developing this drug as a potential treatment for lung cancer using an inhalation route to deliver the drug to tumour sites. The drug is also being assessed as a potential agent to treat some skin cancers.
Looking for a particular Morvus Technology Ltd employee's phone or email?
The Morvus Technology Ltd annual revenue was $6 million in 2026.
Jonathan Beatson-Hird is the Chief Executive of Morvus Technology Ltd.
1 people are employed at Morvus Technology Ltd.
Morvus Technology Ltd is based in Llanvetherine, Monmouthshire.
The NAICS codes for Morvus Technology Ltd are [325, 32, 3254, 32541].
The SIC codes for Morvus Technology Ltd are [28, 283].